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Objective: Dysferlinopathy is a muscular dystrophy with a highly variable clinical presentation and currently
unpredictable progression. This variability and unpredictability presents difficulties for prognostication and clinical trial
design. The Jain Clinical Outcomes Study of Dysferlinopathy aims to establish the validity of the North Star Assessment
for Limb Girdle Type Muscular Dystrophies (NSAD) scale and identify factors that influence the rate of disease progres-
sion using NSAD.
Methods: We collected a longitudinal series of functional assessments from 187 patients with dysferlinopathy over
3 years. Rasch analysis was used to develop the NSAD, a motor performance scale suitable for ambulant and non-
ambulant patients. Generalized estimating equations were used to evaluate the impact of patient factors on outcome
trajectories.
Results: The NSAD detected significant change in clinical progression over 1 year. The steepest functional decline
occurred during the first 10 years after symptom onset, with more rapid decline noted in patients who developed
symptoms at a younger age (p = 0.04). The most rapidly deteriorating group over the study was patients 3 to 8 years
post symptom onset at baseline.
Interpretation: The NSAD is the first validated limb girdle specific scale of motor performance, suitable for use in clini-
cal practice and clinical trials. Longitudinal analysis showed it may be possible to identify patient factors associated with
greater functional decline both across the disease course and in the short-term for clinical trial preparation. Through
further work and validation in this cohort, we anticipate that a disease model incorporating functional performance will
allow for more accurate prognosis for patients with dysferlinopathy.
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Abbreviations
6MWT 6 minute walk test
10MWT 10 meter walk/run test
a-NSAA adapted North Star Ambulatory Assessment
ClinRO clinician reported outcome measure
COS Clinical Outcomes Study of dysferlinopathy
DIF differential item functioning
GEE generalized estimating equations
ICC intraclass correlation coefficient
LGMD limb girdle muscular dystrophy
MFM-20 Motor Function Measure-20
MM Miyoshi myopathy
MMD1 Miyoshi myopathy dystrophy 1
NSAA North Star Ambulatory Assessment
NSAD North Star Assessment for limb girdle type
muscular dystrophies
RFF timed Rise From Floor test
TUG Timed Up and Go test
Dysferlinopathy is a rare, autosomal recessive, inheritedform of muscular dystrophy caused by mutations in
the DYSF gene, which encodes the skeletal muscle protein
dysferlin.1,2 The most common clinical diagnoses associated
with dysferlinopathy are limb girdle muscular dystrophy R2
dysferlin related (formerly LGMD 2B) and Miyoshi myopathy
(MM or Miyoshi myopathy dystrophy 1 [MMD1]).3–5
Although onset typically occurs during young adulthood, clini-
cal presentation is inconsistent, with a wide range of age at
onset, patterns of muscle weakness, and severity, despite a
shared loss of dysferlin protein expression.1,6–8 Likewise, disease
progression is variable; loss of ambulation occurs 5 to 35 years
after onset, whereas a minority of patients remain mildly
affected for decades.9,10 A number of factors that may influence
the clinical phenotype and progression of dysferlinopathy have
been proposed, including exercise and the specific
mutation,6,11,12 although no clear pattern of decline or
phenotype–genotype relationship has been established.
The variable progression of dysferlinopathy presents
numerous challenges for clinical management and identifying
patient groups that could be targeted for clinical trials. The
lack of disease specific, validated clinician reported outcome
measures (ClinRO) of motor performance specific to the
LGMD population has hampered interpretation when moni-
toring progression. Clinically meaningful, validated outcomes
are essential to accurately evaluate change13,14 and response
to therapeutic interventions.15 Existing dysferlinopathy
research suggests the level of decline varies according to the
current functional state and is not stable across short time
periods.16 Showing efficacy in clinical trials is particularly dif-
ficult in slowly progressing and heterogeneous diseases.17,18
Thus, to appropriately power an interventional clinical trial
aiming to slow or stabilize progression in a rare disease like
dysferlinopathy, the natural history of the disease must be
well-characterized using robust and meaningful outcomes,
with a characterized population likely to progress over the
course of a defined clinical trial.
The Jain International Clinical Outcome Study
(COS) of Dysferlinopathy was established to address the
lack of comprehensive natural history data for
dysferlinopathy and to identify and, if necessary, develop
appropriate outcome measures for monitoring disease pro-
gression. Using data from 3 years of follow-up, the aims
of this paper are: part 1) describe the development of the
North Star Assessment for Limb Girdle Type Muscular
Dystrophies (NSAD; formally the North Star Assessment
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for Dysferlinopathy),19 part 2) report on its ability to
detect change over a 1 year period, and part 3) describe
longitudinal disease progression to inform clinical prog-
nostication and identify patients best suited for inclusion
in clinical trials.
Methods
The Jain COS of dysferlinopathy is a multicenter, inter-
national study of patients with a confirmed diagnosis of
dysferlinopathy. Detailed study methods have been pub-
lished previously.9,16 To be included in the Jain COS of
dysferlinopathy, patients were required to have
2 predicted pathogenic mutations in DYSF, or
1 predicted pathogenic mutation plus either absent
dysferlin expression on immunoblot or < 20% dysferlin
monocyte expression.20 Each participating site received
local ethics approval and written informed consent was
obtained for all patients. The study was registered at
ClinicalTrials.gov (NCT01676077).
Participants were evaluated 6 times over the course
of the study: screen, baseline, 6, 12, 24, and 36 months
between November 2012 and March 2018. This multi-
part study includes data on: part 1 = 330 assessments from
154 patients, using available data from a data cut at
20 months after the first patient enrolled. Part 2 = 309
assessments from years 2 and 3 and, part 3 = 187 patients
at 14 sites over 3 years (one original site was excluded due
to the level of missing data). Three-year follow-up was
high with 163 participants (87.2%) completing all study
visits.
Demographic Measures
Self-reported race and patient sex was recorded, and age at
each visit was calculated from the patient’s year of birth.
Symptom duration was calculated as the difference in
years between patient-reported symptom onset (defined as
the onset of muscle weakness) and age at each visit.
Patient-reported clinical diagnosis, as given by diagnosing
clinician, including LGMD2B and MM or other was
recorded. Maximum exercise level prior to disease onset
was classified as none, low, moderate, or high.21
Outcome Measures
A wide range of measures, including function and muscle
strength, were performed in order to establish their useful-
ness in assessing disease progression over time.9 For part
1, two scales of motor performance, the adapted-North
Star Ambulatory Assessment (a-NSAA)22 and Motor
Function Measure-20 (MFM-20),23 were evaluated with
Rasch analysis at year 1, which evolved into the NSAD
used for parts 2 and 3. For part 3, the most sensitive out-
come measures identified during the first year of the study
were selected16 alongside the newly developed NSAD
assessment introduced at year 2. To evaluate the NSAD
across all 3 years, scores prior to year 2 were calculated
based on a-NSAA and MFM-20 items captured at previ-
ous study visits using a defined algorithm; new items were
imputed based on item difficulty hierarchies. Outcome
measures selected showed consistently significant changes
over both 6 and 12 months with relatively high standard-
ized response means, including the 10 meter walk/run
(10MWT) and the ACTIVLIM patient report of daily
function questionnaire. The ACTIVLIM is a validated
patient-reported outcome measure of functional ability
based on perceived difficulty in performing specific activi-
ties of daily living.24,25 Although the 6 minute Walk Test
(6MWT) was previously found to be less sensitive in the
dysferlinopathy population,16 it was included for compari-
son. Timed function tests were converted to velocity mea-
sures (meters or task per second), and 0 m/s or 0 task/s
was assigned when the patient was unable to complete the
test due to disease progression. To appraise usefulness as
inclusion criteria, the Timed Up and Go (TUG) and Rise
from Floor (RFF) tests were evaluated as predictors of
decline to determine whether they could better profile
baseline function.
Statistical Analysis
Part 1: Development of NSAD Using a-NSAA and MFM-20
Collected at Year 1 - Psychometric Evaluation Using
Rasch Analysis. A Rasch analysis examines the extent
to which the observed data (physiotherapists’ ratings of
subject performance on items on the 2 scales) “fit” with
predictions of those ratings from the Rasch model (which
defines how a set of items should perform to generate
reliable and valid measurements).26 The difference
between observed and expected scores indicates the
degree to which a valid measurement is achieved.26,27
Rasch analysis has been used in the development and val-
idation of scales of motor performance in neuromuscular
disorders, including the North Star Ambulatory Assess-
ment (NSAA) and MFM.13,28 Rasch analysis examined
7 tests for reliable and valid measurement and compared
the items of the 2 scales and their targeting ability on the
Jain COS of dysferlinopathy population. Available data
from patients with between 1 and 4 assessments each
over the first year period were included in this analysis.
Data were entered into Rasch Unidimensional Measure-
ment Model26 RUMM2030 software.29
Part 2: Detecting Change Over 1 Year Using the
NSAD. Following part 1 analysis, a proposed amalgam-
ation and rescoring of items from the a-NSAA and
MFM-20 was presented. The new scale, the NSAD, was
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introduced at year 2 visits. The NSAD assessments at
years 2 and 3 visits were examined using the Rasch analy-
sis, as described above, and the Wilcoxon signed rank for
longitudinal change with SPSS 24. Inter-rater reliability
was assessed using intraclass correlation coeffi-
cients (ICCs).
Part 3: Longitudinal Disease Progression Over
3 Years. For part 3, the primary outcome was disease pro-
gression over time, both since symptom onset in years, and
time in months from baseline to subsequent study visits. To
account for correlation between repeated measures of individ-
ual patients, generalized estimating equations (GEEs) with
sandwich variance estimation were used to evaluate change in
functional measures over time. An exchangeable covariance
structure was assumed for all models based on quasi informa-
tion criteria measures suggesting best fit. For direct assessment
of demographic and clinical factors, a 2-tailed p < 0.05 was
considered significant. Nonlinear associations were considered
in symptom duration models by including a quadratic time
term in models to evaluate any plateau effects. All models eval-
uating progression controlled for age at baseline. For all demo-
graphic and clinical factors considered, a factor by time term
was included in models to assess any differences in trajectories;
interaction terms significant at p ≤ 0.20 were noted. To better
visualize potential trajectory differences, continuous measures
with notable interactions were categorized either through com-
monly used age groupings or study-derived quartiles for graph-
ing. Predicted values above or below the possible values for a
given measure were bounded at the upper and lower limits
for plotting. All analyses were completed using SAS ver-
sion 9.4.
Results
Characteristics of the study patients included in the longitudinal
analysis are presented in Table 1. Of the study subjects, 53.5%
were women and most patients identified as non-Hispanic
white (71.1%). Age at baseline ranged from 11 to 86 years and
symptom duration at baseline from 1 to 51 years. Most of the
patients were diagnosed as LGMDR2/2B, and three-quarters of
the participants were ambulant at baseline. Mean follow-up
time was 35.0 ± 5.8 months.
Part 1: Development of the North Star
Assessment for Limb Girdle Type Muscular
Dystrophies
One hundred fifty-eight assessments were available for the
a-NSAA and 172 assessments included in the MFM-20
Rasch analysis. Overall, the a-NSAA and MFM-20 per-
formed well against the battery of psychometric tests but
were not without issue (Table 2).
Adapted North Star Ambulatory Assessment. The a-NSAA
item fit was excellent with good coverage of disease sever-
ity (ie, very few items measured the same level of ability).











Age at baseline, mean (SD),
min/max
38.5 (13.0) 11, 86
Clinical factors
Age at symptom onset,
mean (SD), min/max




17.1 (10.5) 1, 51
Clinical diagnosis
LGMD2B/R2 116 62.0












Number of visits, mean
(SD), min/max
4.8 (0.5) 2, 5
Follow-up time in months,
mean (SD), min/max
35.0 (5.8) 6, 44
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There was minimal floor effect, but some ceiling effect.
Three of 22 items had fit residuals outside the rec-
ommended range, and one item misfit with a significant
v2 probability. Unidimensionality was acceptable (t test
4.2%, binomial test lower 95% confidence interval
[CI] proportion, < 0.01). Reliability was supported by a
high PSI (0.96), similar to Cronbach’s alpha. Six of
22 items displayed disordered item response (scoring)
thresholds. Ten pairs of bilateral items (including stand on
one leg, hopping, and climbing on and off box step) had
residuals that were highly correlated (> 0.40), implying
that a response to one influenced the response to the
other. When left-sided items were removed, the PSI
remained high (0.95), suggesting the dependency did not
artificially inflate reliability. There was no uniform or non-
uniform differential item functioning (DIF) for gender,
indicating that gender did not influence performance on
this scale.
MFM-20. Rasch targeting identified redundant items (too
easy for the population) and a ceiling effect, with a lack of
items measuring stronger ambulant individuals. Eight of
the 20 items had fit residuals outside the recommended
range, and 4 items had a significant v2 probability. Thir-
teen of 20 items had disordered scoring thresholds. Reli-
ability was supported by a high PSI (0.94).
Unidimensionality was not achieved (t test 14.5%, bino-
mial test lower 95% CI proportion, > 0.05). One item
expressed uniform DIF (ankle dorsiflexion), indicating
that the ability to dorsiflex the ankle may be influenced
by gender.
With data for ambulant patients collected on both
scales, it was possible to examine the interaction between
the scales. The a-NSAA measures stronger patients more
effectively with some items from the MFM-20 contribut-
ing to better measurement of weaker and nonambulant
individuals. Ordered response categories (thresholds) are
paramount for accurate scale performance, as a higher
score on individual items must represent a higher level of
overall ability. The a-NSAA had 73% ordered thresholds.
The MFM-20 had only 35% of items with ordered
thresholds, with 4 scoring categories being too complex in
65% of items.
Following this review, 29 items were retained for the
NSAD (all 22 items from the a-NSAA and 7 items from
the MFM-20) with a range from 0 to 54 (the higher the
score the better the ability). The NSAD rescored the dis-
ordered items, removed redundant and duplicate items
(available from the authors), and was re-ordered to
improve efficiency for patients and prevent unnecessary
fatigue. The NSAD replaced the a-NSAA and MFM-20
in years 2 and 3 of the Jain COS of dysferlinopathy.
Part 2: Ability of the NSAD to Detect Change in
1 Year
We examined 309 NSAD assessments, 149 male patients
and 160 female patients from year 2 and year 3 visits. The
NSAD performed well on Rasch analysis (see Table 2).
All but one of the items (Gets to sitting) clearly fit the
construct with appropriate fit residual locations. Four
items at year 2, and 5 items at year 3, misfit with signifi-
cant chi square values of p < 0.05. Reliability was demon-
strated by a high PSI of 0.97. Unidimensionality was
acceptable (binomial test lower 95% CI proportion,
< 0.05). Although a ceiling effect still existed for the stron-
gest and potentially asymptomatic subjects, the motor per-
formance of both ambulant and nonambulant subjects
was targeted successfully by the items of the
NSAD (Fig 1).
In the absence of a second independent rare disease
population on whom to perform traditional scale valida-
tion, Rasch analysis was repeated on 5 randomly generated
cohorts of 80% of the discovery population (see Table 2).
The NSAD performed well in all of these analyses, con-
firming the scale is a fit for purpose instrument in this
population.
The NSAD as a whole detected a statistically signifi-
cant deterioration in the population over 1 year, with a
mean change score of −1.73 points (Wilcoxon signed
rank-sum test p < 0.0001, 95% CI = –2.33 to −1.14;
Table 3). Inter-rater reliability was established with an
ICC of 0.99.
Part 3: Disease Progression
Disease Duration (Time From Symptom Onset). For all out-
comes assessed, a significant decline in function was seen
across disease duration (p < 0.0001), with nonlinear trajec-
tories noted (Table SS1). Plots of the NSAD, 10MWT,
and 6MWT across symptom duration suggested disease
progression for approximately 30 years, at which point
decline reaches the measurement floor or levels off (data
not shown). A milder plateau effect was noted for the
ACTIVLIM.
Results of GEE models suggested that age at onset
may play a role in disease progression (Table SS1). Later
age at onset was associated with better function according
to the NSAD adjusting for disease duration (β = 0.26
points for each year later, 95% CI = 0.06–0.45, p = 0.03),
and patients with earlier age at onset showed faster pro-
gression than those with later onset (p = 0.04). Graphs
suggested the steepest declines occurred during the first
10 years post onset regardless of age at symptom onset,
with earlier onset patients experiencing continued linear
decline compared with later onset patients who began to
plateau (Fig 2A). Additionally, adjusted for disease
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duration, Asian patients performed worse on the 10MWT
(β = −0.53 m/s, 95% CI = –0.89 to −0.16, p = 0.0005)
and 6MWT (β = −0.25, 95% CI = –0.42 to −0.08,
p = 0.004) than White patients, on average, across the dis-
ease course. Slight differences in 10MWT trajectories by
race were also noted (p = 0.11), with Asian and White
patients appearing to decline more quickly than Hispanic
and other patients (Fig 2B). Similarly, on average, women
had higher NSAD scores (β = 4.60 points, 95%
CI = 0.90–8.31, p = 0.02) and slightly better 6MWT
velocities (β = 0.12 m/s, 95% CI = –0.02 to 0.25,
p = 0.08) than male patients, controlling for disease
TABLE 2. Summary Rasch Results for Part 1 - a-NSAA and MFM-20 and Part 2 - NSAD
Item Fit Person Fit Reliability Item Fit






















−0.95 (1.41) −0.12 (0.42) 116 (44) 0.96 16/22 (73%) 19/22a (86%)
1 < p 0.01b





−0.85 (2.17) −0.25 (0.65) 524 (40) 0.94 7/20 (35%) 12/20a (60%)
4 < p 0.01b
1 pair Not acceptable. DIF




Year 2 N =
153 assessments
7 extremes
−0.27 (1.08) −0.26 (0.57) 243.5 (116) 0.97 28/29 (97%) 28/29a
4 < 0.01b
14 pairs Acceptable (< 0.05)
and no DIF for
gender
NSAD
Year 3 N =
156 assessments
6 extremes
−0.51 (1.34) −0.34 (0.61) 350.4 (116) 0.97 28/29 (97%) 26/29a
5 < 0.01b
19 pairs Acceptable (< 0.05)
and no DIF for
gender



























































and no DIF for
gender
*Fit: Defined as fit residual inside the recommended range (−2.50 to 2.50)a and nonsignificant chi squared probability (p < 0.01)b.
a-NSAA = adapted North Star Ambulatory Assessment; DIF = differential item functioning; MFM-20 = Motor Function Measure-20; NSAD = North
Star Assessment for Limb Girdle Type Muscular Dystrophies.
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duration. Some evidence that men progressed faster than
women was noted for the NSAD (p = 0.17; Fig 2C) and
10MWT (p = 0.19), although differences in trajectories
were not significant. Although absolute scores did not dif-
fer based on teenage exercise levels, assessment of disease
trajectories suggested that patients with high exercise levels
during the teenage years progressed slightly faster than
those in the none and moderate exercise groups (Fig 2D;
p = 0.08).
Three-Year Progression. All outcome measures showed
significant decline during the 3-year follow-up period
(p < 0.0001; Table S1). Beta estimates (Table S1) for
follow-up time represented average monthly declines. For
all outcomes, older age at onset and faster TUG and RFF
velocities at baseline were associated with better function,
whereas longer symptom duration was associated with
worse function, controlling for patient age (p < 0.001).
Compared with White patients, patients who identified as
Asian or “other” had lower 10MWT and 6MWT veloci-
ties (p < 0.05).
Age at baseline and symptom duration at baseline
were significantly associated with disease progression dur-
ing the study period, primarily NSAD and 10MWT
decline. The greatest decline during the study period was
seen in patients who had been symptomatic for 3 to
FIGURE 1: Person–item targeting of North Star Assessment for Limb Girdle Type Muscular Dystrophies at year 2 and 3 visits,
people are the top row and items are the bottom row. The strongest patients and the hardest items are on the right, and the
weakest patients and the easiest items are on the left. Good coverage of ability of both ambulant and nonambulant. Ceiling
exists for asymptomatic subjects.
TABLE 3. Means and Change Scores for the NSAD over 12 Months, Years 2 to 3






21.6 (0 to 54)
(n = 140)









28.86 (7 to 54)
(n = 97)









5.73 (0 to 15)
(n = 43)




The patients whose visits fell outside the 12-month visit window for years 3 and 2 were excluded from the analysis (n = 13).
CI = confidence interval; NSAD = North Star Assessment for Limb Girdle Type Muscular Dystrophies.
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8 years (Fig 3A, B). Likewise, patients with earlier age at
symptom onset tended to show a greater decline during
the study period than those with later onset (p = 0.06).
Lower TUG velocity at baseline was associated with
greater decline in self-reported function on the ACTIVLIM
during the follow-up period (p = 0.03), with some evidence
of greater progression on timed function tests (p = 0.08).
Likewise, patients with lower RFF velocity showed larger
declines on the ACTIVLIM (Fig 3C; p = 0.001) and
6MWT (Fig 3D’ p = 0.003), with some evidence of steeper
progression on the 10MWT (p = 0.08). Quartile estimates
suggested little decline over the 3-year study period for
patients with high TUG velocity > 0.13 t/s (~ 7.7 seconds)
or RFF velocity > 0.21 t/s (~ 4.7 seconds).
Sample Size Estimation for Clinical Trial
Readiness. Outcome measures associated with decline over
a short time period identified in 3-year GEE models were
selected to characterize possible clinical trial inclusion
criteria. Sample size is highly dependent on estimated treat-
ment effect and variability around the estimate, whereby
larger effects and decreased variability necessitate smaller
samples. Sample size was estimated using PASS 15 software
(Table 4). Mean decline and standard deviation for each
6 and 12-month period (± 2 months) were calculated. Sam-
ple sizes for a hypothetical clinical trial targeting halting of
progression with the NSAD as the outcome measure ranged
from 14 using the strictest inclusion criteria to 32 based on
symptom duration at baseline alone for a 1-year trial and
32 to 52 for a 6-month trial based on the same criteria.
Discussion
Part 1 of this study evaluated the suitability of the a-
NSAA and MFM-20 scales to measure motor performance
in dysferlinopathy. The subsequent new scale, the NSAD,
addressed the measurement issues within these 2 scales,
re-ordered items to improve efficiency and reduce patient
fatigue, and made the scale applicable for both ambulant
and nonambulant patients. Analysis in part 2 confirmed
that the NSAD could detect change in clinical progression
of individuals with dysferlinopathy over 1 year and dem-
onstrated excellent inter-rater reliability. This further sup-
ports the reported results for the first year of the Jain
FIGURE 2: Outcome trajectories across symptom duration by patient characteristic. Fitted regression lines with 95% confidence
intervals from generalized estimating equation modeling for (A) North Star Assessment for Limb Girdle Type Muscular
Dystrophies (NSAD) score by age at symptom onset, (B) 10 meter walk/run test (10MWT) by race/ethnicity, (C) NSAD score by
sex, and (D) 10MWT by teen exercise level.
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COS of dysferlinopathy, where the a-NSAA was suggested
as a possible primary outcome for ambulant patients.16
The NSAD tests the abilities of anterior and poste-
rior muscles of the leg and calf, which positions the assess-
ment well to measure change in motor function across
other LGMDs and conditions involving the pelvic girdle,
such as Becker muscular dystrophy. The NSAD is cur-
rently being utilized in longitudinal natural history studies
of LGMD types, including LGMDR1 Calpain3 related,
LGMDR3 alpha-sarcoglycan related, and LGMDR4 beta-
sarcoglycan related.30,31 In these populations, the NSAD
was highly correlated to the 100 meter walk/run and RFF
tests, and differentiated rates of functional decline.30,31 It
is also being utilized as an end point to demonstrate
improvement in motor function in the ongoing phase I
gene therapy trial for LGMD R4.15 Further work is being
undertaken to examine its relationship to patient-reported
outcome measures and validation in other diseases.
Results from part 3 suggested disease progression
primarily occurs during the first 30 years after symptom
onset, at which point progression levels off. Patients with
an earlier disease onset may represent a more severe phe-
notype. Patients earlier on in their disease, particularly
those 3 to 8 years from symptom onset, showed the
steepest rate of progression, particularly in the NSAD and
10MWT over 3 years of follow-up. This finding is
supported by a small study of 18 patients with
dysferlinopathy where patients progressed from normal
function to difficulty standing at an average of 8 years
after disease onset.11 Baseline TUG and RFF tests pro-
vided additional information, suggesting more noticeable
declines in other outcome measures among patients with
velocity measures below the highest quartile.
We previously estimated 46 moderately affected
ambulant patients would be needed to show a halting of
disease progression over 1 year on the a-NSAA.16 Limiting
inclusion criteria to patients 3 to 8 years from onset, with
the NSAD as the outcome, could reduce this number to
32 and with timed function test criteria to 14. However,
the necessary sample size must be balanced against the
available population that meets the inclusion criteria. In
the present study, only 40 patients fell into the 3 to
FIGURE 3: Functional outcome trajectories during the study period by patient characteristic. Fitted regression lines with 95%
confidence intervals from generalized estimating equation modeling for (A) North Star Assessment for Limb Girdle Type
Muscular Dystrophies (NSAD) score among symptom duration ≤ 10 years, (B) 10MWT among symptom duration ≤ 10 years,
(C) ACTIVLIM by Rise from Floor velocity quartile, and (D) 6 minute walk test by Rise from Floor velocity quartile.
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Disease duration 3–8 yr
6 mo
NSAD −1.53 (1.93) 202 92 52 38 26
ACTIVLIM −0.74 (1.61) 598 268 152 106 70
10MWT −0.14 (0.20) 260 116 68 48 32
6MWT −0.04 (0.07) 388 174 100 70 46
1 yr
NSAD −2.81 (2.68) 116 54 32 22 16
ACTIVLIM −1.31 (2.03) 310 138 78 56 36
10MWT −0.20 (0.18) 104 48 28 20 14
6MWT −0.09 (0.09) 128 58 34 24 18
Disease duration 3–8 yr and either TUG velocity < 0.13 or Rise from Floor velocity < 0.21
6 mo
NSAD −1.90 (1.91) 130 60 34 26 18
ACTIVLIM −1.33 (1.39) 140 64 38 26 18
10MWT −0.15 (0.21) 250 112 64 46 30
6MWT −0.04 (0.06) 286 128 74 52 34
1 yr
NSAD −2.78 (2.66) 118 54 32 24 16
ACTIVLIM −2.14 (1.75) 86 40 24 18 12
10MWT −0.20 (0.13) 56 26 16 12 10
6MWT −0.11 (0.08) 70 32 20 14 10
Disease duration 3–8 yr and TUG velocity < 0.13 and Rise from Floor velocity < 0.21
6 mo
NSAD −2.20 (2.14) 122 56 32 24 16
ACTIVLIM −1.39 (1.64) 178 80 46 34 22
10MWT −0.07 (0.08) 166 76 44 32 22
6MWT −0.03 (0.07) 684 306 174 122 78
1 yr
NSAD −3.07 (1.79) 46 22 14 10 8
ACTIVLIM −1.80 (1.25) 64 30 18 14 10
10MWT −0.16 (0.10) 52 24 16 12 8
6MWT −0.12 (0.10) 90 42 24 18 12
aCalculations are based on an observed change in outcome score in untreated patients, representing the expected control effect. Numbers quoted repre-
sent the total sample size based on equally sized treatment and control groups.
6MWT = 6 minute walk test; 10MWT = 10 meter walk/run test; NSAD = North Star Assessment for Limb Girdle Type Muscular Dystrophies;
TUG = Timed Up and Go test.
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8 years post-onset criteria across 14 sites, whereas just
10 patients met the most stringent criteria, highlighting
the difficulty in meeting specific inclusion criteria for clin-
ical trials. In addition, caution should be taken when con-
sidering years from symptom onset in inclusion criteria as
onset of symptoms is often subjective, especially in retro-
spect. Although the 6MWT and ACTIVLIM remained
sensitive measures of decline for more severely affected
patients, timed function tests based on walking, including
the 6MWT, are unsuitable once a patient loses ambula-
tion, and are thus limited in terms of clinical and research
utility.
Although we think the development of the LGMD-
specific NSAD motor performance measure provides a
valuable assessment tool previously lacking in
dysferlinopathy, a limitation in the present investigation
was the change to the scale mid-study. To address this
issue, a detailed conversion plan was developed by expert
physiotherapists; average decline per year estimated by
GEE models (−1.7 points/year) was similar to mean
annual changes of directly collected NSAD scores from
year 2 to year 3 (−1.8).
The present study further supports results reported
previously for the first year of study follow-up.16 Annual
change scores estimated from GEE models controlling for
age were similar to median change scores reported previ-
ously for the outcome measures considered. The use of
GEE modeling here allowed us to directly assess differ-
ences in rates of disease progression, which may have both
clinical and trial implications.
A major strength of the present study was the avail-
ability of a large, diverse, multinational cohort, with char-
acterized long-term follow-up that permitted assessment of
longitudinal progression and trends previously unavailable.
However, despite this large sample, certain patient groups
remained small given the rarity of the disease; for example,
only 12 patients identified as Hispanic and 5 as Black
across all sites. Thus, findings involving race should be
interpreted with caution. We aim to address this in future
studies by expanding to additional sites.
The present investigation provided a broad estimate
of functional trajectories across disease duration and aimed
to identify patient groups and outcome measures for effi-
ciently powered clinical trials. Future studies will explore
additional factors, including genetic and biomarkers, as
well as examine the role of the upper limb. Continued
follow-up of the present population will also permit a
more detailed understanding of long-term performance
trajectories and functional loss. The NSAD is the first
LGMD specific scale of motor performance. It allows
measurements of patients in both the ambulant and non-
ambulant stages of disease, providing a continuous scale of
functional ability throughout the course of the disease,
making it suitable for clinic, natural history studies, and
interventional clinical trials.
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